Subscribe free

Cytoreductive Surgery & Peritoneum ·

Repeat Cytoreduction and HIPEC Boost Survival in Recurrent Appendiceal Adenocarcinoma

When dealing with recurring mucinous appendiceal adenocarcinoma, undergoing repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be a game-changer. This study from MD Anderson Cancer Center reveals that patients who opt for repeat CRS/HIPEC enjoy similar recurrence-free survival compared to those initially treated, and even better overall survival than patients relying solely on systemic chemotherapy. These findings emphasize the potential benefits of this treatment strategy, especially when administered by experienced teams in high-volume centers.

Journal Article by Bhutiani N, Grotz TE (…) Fournier KF et 12 al. in Ann Surg Oncol

© 2023. The Author(s).

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →